TP53 and metastatic prostate carcinoma: Moreover, the loss of 17p rises up to 63% (95 out of 150) in metastatic prostate cancer, whereas TP53 mutation and homozygous deletion account for only 39 and 6% respectively (Fig. 1e, f).